Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3;148(9):3153-3169.
doi: 10.1093/brain/awaf129.

Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma

Affiliations

Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma

Nishant Soni et al. Brain. .

Abstract

Glioblastoma is the most aggressive and lethal adult brain tumour. The cellular heterogeneity within the tumour microenvironment plays a crucial role in the complexity of treatment and poor survival. Glioblastoma is typically classified into three molecular subtypes (classical, mesenchymal and proneural) associated with EGFR, NF1 and PDGFRA genetic drivers, respectively. Yet, the role of these driver mutations in the glioblastoma tumour microenvironment is not fully understood. Here, we used single-cell RNA sequencing of genetically engineered mouse glioblastoma models incorporating human-relevant EGFRvIII, PDGFB and NF1 driver mutations to characterize the genotype-immunophenotype relationship of the three glioblastoma subtypes systematically. Murine genetic glioblastoma models at the single-cell level effectively mimic the inter- and intra-tumour heterogeneity found in human counterparts. Our analysis revealed that PDGFB-driven tumours were more proliferative and enriched for Wnt signalling interactions, whereas EGFRvIII-driven tumours showed an elevated interferon signalling response. Moreover, Nf1-silenced tumours displayed higher myeloid abundance, myeloid immunosuppressive interactions involving Spp1, regulatory T-cell infiltration and expression of immune checkpoint molecule Ctla4. Overall, we established a human-mouse analytical platform for genotype-aware target discovery and validation, which offers promising new avenues for more effective, personalized treatments in glioblastoma.

Keywords: genetically engineered mouse models; glioblastoma; myeloid cell diversity; single-cell genomics; tumour heterogeneity.

PubMed Disclaimer

Conflict of interest statement

The authors report no competing interests.

References

    1. Price M, Ryan K, Shoaf ML, et al. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015–2019. Neurooncol Pract. 2024;11:5–25. - PMC - PubMed
    1. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):v1–v100. - PMC - PubMed
    1. Zhao J, Chen AX, Gartrell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:462–469. - PMC - PubMed
    1. Bagley SJ, Logun M, Fraietta JA, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: Phase 1 trial interim results. Nat Med. 2024;30:1320–1329. - PubMed
    1. Tang F, Wang Y, Zeng Y, Xiao A, Tong A, Xu J. Tumor-associated macrophage-related strategies for glioma immunotherapy. NPJ Precis Oncol. 2023;7:78. - PMC - PubMed